Aim: We have analyzed if, in genotype 1 HCV infected patients, antiviral treatment with pegylated interferon plus ribavirin has the same efficacy in term of sustained virological response (SVR) in subtypes 1a respect to 1b and if these two populations of patients have different clinical characteristics. Methods and Patients: Three hundred and one naïve patients with genotype 1 chronic active hepatitis C received peginterferon alfa 2a or alfa 2b plus ribavirin (15mg/kg/day) for 48 weeks.The primary end point was SVR by intention to treat. Results: All the demographic and clinical characteristics of the patients are reported in the Table. SVR was achieved in 56% (71 pts) of patients with subtype 1a and in 38% (66 pts) of patients with subtype 1b (p<0.001). The percentage of patients who first achieved undetectable HCVRNA at weeks 4 and 12 were respectively 49% and 58% in subtype 1a and 35% and 41% in subtype 1b. Logistic regression analysis identified an HCVRNA<400000 IU/ml (OR 3.5 95% CI 1.5-7.3 p<0.001)and Fibrosis score <2 (OR 4.2, 95% CI 3.3-7.5 p<0.001) as independent parameters for SVR in subtype 1a HCV infected patients. Conclusion: Compared to patients with genotype 1b, the patients with genotype 1a had a more significant SVR. HCVRNA<400000 UI/ml and lower fibrosis score were independent parameters predictive of SVR in genotype 1a patients.

INFLUENCE OF HCV GENOTYPE 1A AND GENOTYPE 1B ON THE VIROLOGICAL RESPONSE TO ANTIVIRAL THERAPY

Picardi A;
2010-01-01

Abstract

Aim: We have analyzed if, in genotype 1 HCV infected patients, antiviral treatment with pegylated interferon plus ribavirin has the same efficacy in term of sustained virological response (SVR) in subtypes 1a respect to 1b and if these two populations of patients have different clinical characteristics. Methods and Patients: Three hundred and one naïve patients with genotype 1 chronic active hepatitis C received peginterferon alfa 2a or alfa 2b plus ribavirin (15mg/kg/day) for 48 weeks.The primary end point was SVR by intention to treat. Results: All the demographic and clinical characteristics of the patients are reported in the Table. SVR was achieved in 56% (71 pts) of patients with subtype 1a and in 38% (66 pts) of patients with subtype 1b (p<0.001). The percentage of patients who first achieved undetectable HCVRNA at weeks 4 and 12 were respectively 49% and 58% in subtype 1a and 35% and 41% in subtype 1b. Logistic regression analysis identified an HCVRNA<400000 IU/ml (OR 3.5 95% CI 1.5-7.3 p<0.001)and Fibrosis score <2 (OR 4.2, 95% CI 3.3-7.5 p<0.001) as independent parameters for SVR in subtype 1a HCV infected patients. Conclusion: Compared to patients with genotype 1b, the patients with genotype 1a had a more significant SVR. HCVRNA<400000 UI/ml and lower fibrosis score were independent parameters predictive of SVR in genotype 1a patients.
File in questo prodotto:
File Dimensione Formato  
Hepatology 2010 Abstract Pellicelli Picardi 23992.pdf

non disponibili

Tipologia: Altro materiale allegato
Licenza: Non specificato
Dimensione 1.43 MB
Formato Adobe PDF
1.43 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12610/14535
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact